"The Russian vaccine" Sputnik V "in the course of clinical trials and large-scale vaccination of the population shows high efficiency and safety," RIA Novosti quotes him.
According to Fisenko, the decision to register Sputnik V was made taking into account its high efficiency, including data on the safety of the adenovirus vector platform, which the Gamaleya Center used to create other vaccines.
Earlier, the director of the Gamaleya Center, Alexander Gintsburg, said that by the end of the New Year holidays, about 1.5 million doses of the coronavirus vaccine will go into civil circulation in Russia.